Abbott (NYSE: ABT) received FDA investigational device exemption (IDE) approval for its coronary intravascular lithotripsy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback